FORM 17A

Notice of Normal Course Issuer Bid ("NCIB")

Type of Notice: ☒ Draft ☐ Revised ☐ Final

Name of Listed Issuer: Britannia Life Sciences Inc. (the "Listed Issuer").

Trading Symbol: BLAB

Date: July 29, 2026.

If this is an update to a prior notice, provide date(s) of prior notice(s): Not applicable

Date of news release(s) disclosing the NCIB: News release will be filed concurrently with the final notice.

Number of outstanding listed securities as of date of this notice:

175,320,522 common shares

Maximum number of securities subject to the NCIB: 8,766,026 common shares

Percentage of the public float to be acquired under the bid: Up to 5%

Average Daily Trading Volume (as defined in CSE Policy): 134,168 common shares

Purchasing CSE Dealer and trader ID: Hampton Securities Limited, trader ID 94

Will securities be cancelled after purchase: ☒ Yes ☐ No

If "No", provide details: ____

1. If this is a revised notice, state the reason for revisions.

   Not applicable

2. Number of securities that may be acquired under the bid: If the Listed Issuer has determined a specific number of shares, provide that number rather than the simply stating the maximum. If not, state the amount as a percentage of the outstanding or of the public float.

   Up to 8,766,026 common shares, representing approximately 5.0% of the 175,320,522 common shares issued and outstanding as at the date of this notice.

3. Provide the date of expiry, which will be not more than 1 year from the date on which purchases are first permitted.

The NCIB will be in effect for a twelve (12) month period. Purchases may commence on or about August 10, 2026 (two trading days following the later of the posting of the final notice and the disclosing news release) and will terminate on or about August 9, 2027, or such earlier date as the Listed Issuer completes its purchases or otherwise terminates the bid.

4. State on which exchange(s) purchases will be made, and whether purchases will be made by any means other than open market transactions.

   Purchases will be made through the facilities of the CSE and any other permitted alternative Canadian trading systems. All purchases will be made by means of open market transactions. No purchases will be made other than by open market transactions.

5. Describe any restrictions on the price the Listed issuer will pay for securities, other than those in the Exchange Requirements.

   There are no restrictions on the price the Listed Issuer will pay for the common shares other than those imposed by Exchange Requirements. In accordance with CSE Policy 6, purchases will be made at a price that is not higher than the last independent trade of the common shares at the time of purchase.

6. State the reason or business purpose for the bid.

   The board of directors of the Listed Issuer believes that, from time to time, the market price of the common shares does not adequately reflect the underlying value of the Listed Issuer's assets and the prospects of its business. The board is of the view that the repurchase of common shares at such prices represents an attractive use of the Listed Issuer's available cash resources and is in the best interests of the Listed Issuer, enhancing long-term shareholder value. Common shares purchased under the NCIB will be cancelled.

7. Include a summary of any appraisal or valuation known to the directors or officers of the Listed Issuer's material assets or its securities completed in the previous two years, together with a statement of where and when a copy of the appraisal or valuation may be inspected.

   To the knowledge of the directors and officers of the Listed Issuer, after reasonable inquiry, no appraisal or valuation of the Listed Issuer's material assets or its securities has been completed in the previous two years.

8. Identify any persons acting jointly or in concert with the Listed Issuer in connection with the issuer bid or purchases of securities of the Listed Issuer in the previous twelve months, including a trustee or agent as described in Policy 6.10.

To the knowledge of the directors and officers of the Listed Issuer, after reasonable inquiry, there are no persons acting jointly or in concert with the Listed Issuer in connection with the issuer bid.

9. Give details of any purchases by the Listed Issuer or persons acting jointly or in concert with the Listed Issuer of the securities that are the subject of the bid in the previous twelve months.

Neither the Listed Issuer nor, to its knowledge, any person acting jointly or in concert with the Listed Issuer has purchased any common shares of the Listed Issuer in the previous twelve months.

10. Identify every director or senior officer of the Listed Issuer who intends to sell securities of the Listed Issuer during the course of the bid. Where their intention is known after reasonable inquiry, state the name of every associate of a director or senior officer of the issuer, person acting jointly or in concert with the Listed Issuer in connection with the issuer bid or purchases of securities of the Listed Issuer in the previous twelve months, or person holding 10% or more of any class of equity securities of the issuer, who intends to sell securities of the Listed Issuer during the course of the bid:

To the knowledge of the Listed Issuer, after reasonable inquiry, no director or senior officer, no associate of a director or senior officer, no person acting jointly or in concert with the Listed Issuer, and no person holding 10% or more of any class of equity securities of the Listed Issuer intends to sell common shares of the Listed Issuer during the course of the bid

11. Describe any direct or indirect benefits any person named in the previous section will receive from selling or not selling shares of the Listed Issuer during the bid. An answer is not required if the benefit will be the same as the benefit to any other shareholder who sells or does not sell during the bid.

Not applicable. No director or senior officer (or associate thereof) has indicated an intention to sell common shares during the course of the bid. Any benefit received by a selling shareholder will be the same as the benefit available to any other shareholder who sells or does not sell common shares during the bid.

12. Where the Listed Issuer has a class of Restricted Securities, specify whether the bid includes a bid for Restricted Securities.

The Listed Issuer has a single class of common shares outstanding and does not have any Restricted Securities. Accordingly, the bid does not include a bid for Restricted Securities.

Certificate

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).

4. All of the information in this Form is true.

Dated: July 29, 2026.

Peter Shippen
Name of Director or Senior Officer

Signature

Chief Executive Officer
Official Capacity